Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28750369 | 0.98 | CHRNB2 (0.38) | CHRNB2CHRNA4LTA4HTSHRALDH1A1 | |
| SCHEMBL160311 | 0.83 | ALDH1A1 (0.46) | CHRNB2CHRNA4TSHRALDH1A1 | |
| SCHEMBL996139 | 0.82 | HRH3 (0.39) | TSHRALDH1A1 | |
| SCHEMBL27755603 | 0.81 | ALDH1A1 (0.44) | CHRNB2CHRNA4TSHRALDH1A1 | |
| SCHEMBL28636919 | 0.81 | ALDH1A1 (0.44) | CHRNB2CHRNA4TSHRALDH1A1 | |
| SCHEMBL28558829 | 0.81 | ALDH1A1 (0.44) | CHRNB2CHRNA4TSHRALDH1A1 | |
| SCHEMBL3301820 | 0.76 | HDAC1 (0.32) | LTA4HTSHR | |
| SCHEMBL5448128 | 0.74 | ADRA2B (0.35) | TSHRALDH1A1 | |
| SCHEMBL5391395 | 0.74 | ALDH1A1 (0.30) | TSHRALDH1A1 | |
| SCHEMBL998683 | 0.74 | HRH3 (0.42) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1296982-B1 | 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1670739-A4 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | claimed |
| US-20070027186-A1 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | claimed |
| US-7153960-B2 | Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | claimed |
| EP-1553947-A4 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1670739-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | claimed |
| US-6998408-B2 | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-02-14 | — | — | US | claimed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | claimed |
| WO-2002094197-A2 | BICYCLIC INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| WO-2002080853-A2 | FUSED HETEROCYCLIC INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020119986-A1 | Heteroaryl- phenyl heterobicyclic factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | claimed |
| US-20020103202-A1 | Heteroaryl-phenyl substituted factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | claimed |
| US-20020022614-A1 | Thrombin or factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-21 | — | — | US | claimed |
| WO-2002002519-A2 | THROMBIN OR FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002000647-A1 | HETEROARYL-PHENYL SUBSTITUTED FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000651-A2 | FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000655-A1 | 1 - (HETEROARYL-PHENYL) - CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027186-A1 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | F2, TFPI, TFPI2 | CHRNB2 3927/4885CHRNA4 2553/4885LTA4H 1067/4885 |
| US-20020022614-A1 | Thrombin or factor Xa inhibitors | TFPI, PLAT, SPINT2 | CHRNB2 4860/4885CHRNA4 4848/4885LTA4H 483/4885 |
| US-20020103202-A1 | Heteroaryl-phenyl substituted factor Xa inhibitors | F12, F3, TFPI | CHRNB2 4154/4885CHRNA4 4397/4885LTA4H 1510/4885 |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | CHRNB2 3852/4885CHRNA4 3607/4885LTA4H 2668/4885 |
| US-20020119986-A1 | Heteroaryl- phenyl heterobicyclic factor Xa inhibitors | SERPINC1, TFPI, F12 | CHRNB2 4231/4885CHRNA4 4368/4885LTA4H 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.